Sodium Pyrophosphate
CAS 7722-88-5
Sodium Pyrophosphate (CAS 7722-88-5) is a pharmaceutical compound with 1 bioactivity target and 6 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 23222.275 nM | 4 | - |
| Farnesyl pyrophosphate synthase Enzyme |
Ki | 4.53 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Respiratory tract infection bacterial | 19 | 110.396 | 10060693 |
| Respiratory tract infection viral | 19 | 94.613 | 10062106 |
| Cytokine release syndrome | 25 | 81.864 | 10052015 |
| Respiratory tract infection | 20 | 51.297 | 10062352 |
| Pulmonary embolism | 20 | 28.618 | 10037377 |
| Platelet count decreased | 21 | 28.546 | 10035528 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| TETRASODIUM PYROPHOSPHATE | 1364532 | SU | MTHSPL |
| SODIUM PYROPHOSPHATE | 1364532 | SU | MTHSPL |
| Sodium Pyrophosphate | 1364532 | SU | MTHSPL |
| sodium pyrophosphate | 1364532 | PIN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sodium Pyrophosphate used for in pharmaceutical contexts?
Sodium Pyrophosphate (CAS 7722-88-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sodium Pyrophosphate?
Sodium Pyrophosphate has 6 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Respiratory tract infection bacterial, Respiratory tract infection viral, Cytokine release syndrome, Respiratory tract infection, Pulmonary embolism. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sodium Pyrophosphate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for TETRASODIUM PYROPHOSPHATE with EU status "permitted".
What clinical phase is Sodium Pyrophosphate in?
No phase 1-4 clinical development badge is rendered for Sodium Pyrophosphate because the matched compound identifier rows do not contain a max-phase value.
What bioactivity targets are documented for Sodium Pyrophosphate?
Sodium Pyrophosphate has 2 bioactivity rows in this page query. Rendered target entries include Farnesyl pyrophosphate synthase.